Journey Medical Corp
Statements
Cash Flow
Journey Medical Corp (DERM) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -1.7 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 16 | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -28 | -21 | 0.7 | -25 | -15 | -32 | -32 | -55 | -23 | -135 | -78 | -69 | -62 | -6.1 | 0.6 | 0.6 | -1.1 | 5.1 | 1.4 | -7.4 | 7.1 | -3.2 | 0.9 | -3.3 | -7.3 | -3.8 | -1.0 | 4.0 | 19 | -17 | -5.0 | -5.2 | -1.2 | 2.2 | -2.8 | -0.9 | -2.4 | -6.3 | 2.9 | -1.7 | -7.5 | |
| -0.3 | 0.8 | 0.0 | 0.1 | 0.3 | 0.8 | -0.5 | 1.9 | 2.6 | 0.4 | 0.2 | 0.2 | 0.1 | 0.1 | 0.4 | 0.4 | 0.4 | 0.4 | 0.6 | 0.8 | 0.7 | 0.5 | 1.0 | 1.0 | 1.0 | 1.2 | 1.1 | 1.1 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 1.0 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.0 | 4.3 | |
| 2.5 | 2.9 | 3.1 | 4.6 | 5.1 | 5.5 | 5.5 | 7.5 | 7.3 | 7.9 | 7.1 | 8.0 | 7.5 | 6.7 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.4 | 0.8 | 0.8 | 1.4 | 1.4 | 0.6 | 0.9 | 0.6 | 0.5 | 1.4 | 1.7 | 1.6 | 1.4 | 1.3 | 1.3 | 1.9 | 1.8 | 1.0 | 1.4 | 6.1 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.2 | – | 0.8 | 7.3 | 7.3 | 13 | 0.9 | 1.0 | 1.7 | 4.5 | 4.5 | 4.5 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 111 | -33 | 4.2 | 163 | 258 | -143 | -76 | -46 | -51 | -35 | -22 | 84 | -3.3 | -24 | -1.6 | -1.6 | -1.7 | 3.2 | 0.1 | 2.2 | 9.3 | 3.1 | 0.3 | 2.2 | 0.0 | 3.7 | 7.2 | 6.4 | 0.4 | -16 | 3.1 | -4.5 | -0.9 | -1.5 | -1.5 | 0.7 | -3.2 | -8.0 | 2.9 | -5.8 | -14 | |
| 0.0 | 0.0 | 0.6 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 8.8 | 1.2 | 20 | 0.0 | 0.0 | 20 | 5.0 | 0.0 | 0.0 | 5.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 9.7 | -136 | -16 | 2.6 | -48 | 7.8 | -67 | 47 | -90 | -17 | 4.1 | 26 | -37 | -61 | – | – | -1.0 | -0.2 | -8.8 | -8.8 | -8.8 | -1.2 | -20 | – | – | -20 | -5.0 | – | – | 5.0 | – | – | – | -15 | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.4 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -119 | 155 | 14 | -202 | -216 | 25 | 98 | -289 | 112 | 1.2 | 1.0 | 141 | 0.9 | -0.2 | – | – | – | – | – | – | – | -1.6 | -0.4 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -1.4 | – | -1.4 | 7.0 | 7.0 | 0.8 | 12 | 4.0 | 4.0 | -13 | -13 | -13 | – | – | – | – | -0.7 | 12 | -0.6 | 0.0 | 0.0 | 16 | 0.0 | 0.0 | 16 | |
| 137 | 1.3 | 1.0 | 183 | 279 | -0.1 | 1.1 | 0.2 | 1.0 | 1.2 | 34 | 140 | 0.9 | 39 | – | – | 5.0 | -0.5 | 9.4 | 0.6 | 11 | 32 | 11 | 0.1 | 4.0 | 0.9 | 0.1 | -13 | -11 | 19 | 1.6 | 5.0 | -0.3 | 11 | 3.6 | 0.2 | 7.0 | 5.4 | 0.2 | 0.2 | 13 | |
| 119 | -155 | -14 | 160 | 216 | -25 | -98 | -6.6 | -409 | -151 | -40 | 97 | -99 | -28 | 0.6 | 0.6 | -2.1 | 4.4 | 11 | -6.8 | 9.5 | 27 | -7.8 | -3.2 | -3.3 | -2.9 | -5.9 | -9.1 | 7.8 | 2.7 | -3.4 | -0.1 | -1.5 | -2.2 | 0.8 | -0.8 | 4.7 | -0.9 | 3.1 | -1.6 | 5.4 | |
| -28 | -21 | 0.0 | -25 | -15 | -32 | -32 | -55 | -24 | -135 | -78 | -69 | -62 | -6.2 | 0.6 | 0.6 | -1.1 | 4.9 | 1.4 | -7.4 | 7.1 | -4.4 | -19 | -3.3 | -7.3 | -3.8 | -6.0 | 4.0 | 19 | -17 | -5.0 | -5.2 | -1.2 | 2.2 | -2.8 | -0.9 | -2.4 | -6.3 | 2.9 | -1.7 | -7.5 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.